Latest News & Features
Europe
Partnering with AI vendors can open doors for startups and small companies but it also brings serious risks. Experts at AI & IP Europe share key lessons on contracts, data ownership, ring-fencing, monitoring, and exit planning, as Marisa Woutersen reports. 11 November 2025
Europe
Cosmetics companies are increasingly using biological molecules in product applications but will need to draft patent applications carefully in this ‘grey area’. 11 November 2025
Big Pharma
According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge. 10 November 2025
Careers
The ‘distinguished litigator’ rejoins six former colleagues at the new firm, bringing expertise in high-stakes disputes representing global tech and life sciences clients. 7 November 2025
Asia
Sister title WIPR’s China Patent Rankings detail the firms and individuals most capable of handling patent matters in the country, from litigators with winning streaks to global strategists. 7 November 2025
Big Pharma
Judge delivers major setback to pharma giant’s efforts to scupper rival’s surprise bid, in an increasingly bitter feud over an obesity drug biotech. 6 November 2025
Careers
Womble Bond Dickinson has expanded its West Coast footprint with the addition of a seasoned patent litigator, strengthening the firm’s life sciences capabilities amid rising IP disputes and rapid biotech innovation. 6 November 2025
Americas
Barley Snyder partner Sal Anastasi—woodworker, pilot, and now head of the AIPLA—speaks to WIPR about the urgent need for clarity in patent eligibility, and why collaboration and engagement are essential as the USPTO ushers in a period of rapid change. 6 November 2025
Unified Patent Court
Growing clout, powerful remedies, and efficiency are making the UPC a game-changer in global litigation, according to LSPN Europe experts. Tom Phillips reports. 4 November 2025
Americas
Merck Serono has failed to convince a US appeals court to overturn a PTAB decision invalidating two dosing regimen patents for cladribine. 4 November 2025